Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group AL.4 (DFCI 01-175)- A Multi-Center Phase II Study in Adults with Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol

The purpose of this trial was to determine whether an intensive pediatric ALL chemotherapy protocol for children <18 years old would be tolerable for 18-50-year-old adults and would result in improved outcomes. A total of 100 patients were enrolled between June 2002 and February 2008 from 13 institutions. The results of this study show that the use of a pediatric-inspired chemotherapy regimen is associated with excellent long-term results in children, and can be safely and efficaciously applied to adults aged 18-50 years.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29: 526-34, 2014.

Canadian Cancer Trials Group MAC.4 (IBCSG 24-02 SOFT)- A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
Canadian Cancer Trials Group MAC.5 (IBCSG 25-02 - TEXT) - A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szoke J, Doimi F, Villani L, Pizzolitto S, ?hlschlegel C, Sessa F, Peg C?mara V, Rodr?guez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 154: 275-86, 2015.

Canadian Cancer Trials Group MA.14 - A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

Sgroi D, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel C, Erlander M, Pritchard K, Han L, Shepherd L, Goss P, Pollak M. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an Canadian Cancer Trials Group MA.14 study. Breast Cancer Research 18: 1, 2016.